BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23470829)

  • 21. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
    Bassan R; Rossi G; Pogliani EM; Di Bona E; Angelucci E; Cavattoni I; Lambertenghi-Deliliers G; Mannelli F; Levis A; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Borghero C; Romani C; Spinelli O; Tosi M; Oldani E; Intermesoli T; Rambaldi A
    J Clin Oncol; 2010 Aug; 28(22):3644-52. PubMed ID: 20606084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.
    Ottmann OG; Pfeifer H
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S43-6. PubMed ID: 19561414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prolonged molecular response induced by imatinib in Philadelphia positive acute lymphoblastic leukemia A case report and brief review].
    Raissi A; Bouaouad M; Drideb NA; Jennane S; Mahtat el M; Doghmi K; Mikdame M
    Ann Biol Clin (Paris); 2015; 73(2):195-8. PubMed ID: 25847743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols.
    Ribera JM; García O; Fernández-Abellán P; Lavilla E; Bernal MT; González-Campos J; Brunet S; Monteserín MC; Montesinos P; Sarrá J; Calbacho M; Alvarez-Larrán A; Tormo M; Oriol A;
    Br J Haematol; 2012 Nov; 159(4):485-8. PubMed ID: 22966847
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Gruber F; Mustjoki S; Porkka K
    Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lim SN; Joo YD; Lee KH; Kim DY; Lee JH; Lee JH; Chi HS; Yun SC; Lee WS; Lee SM; Park S; Kim I; Sohn SK; Moon JH; Ryoo HM; Bae SH; Hyun MS; Kim MK; Kim HJ; Yang DH; Eom HS; Lee GW; Jung CW; Won JH; Kim H; Lee JH; Shin HJ; Jang DY
    Am J Hematol; 2015 Nov; 90(11):1013-20. PubMed ID: 26228525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of ovarian stimulation for fertility preservation in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after treatment with dasatinib.
    Ogawa T; Ogi M; Hirata S
    J Obstet Gynaecol Res; 2021 Mar; 47(3):1182-1185. PubMed ID: 33469980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kodama Y; Manabe A; Kawasaki H; Kato I; Kato K; Sato A; Matsumoto K; Kato M; Hiramatsu H; Sano H; Kaneko T; Oda M; Saito AM; Adachi S; Horibe K; Mizutani S; Ishii E; Shimada H
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28084041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.
    Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China.
    Gao L; Zhang C; Gao L; Liu Y; Su Y; Wang S; Li B; Yang T; Yuan Z; Zhang X
    J Hematol Oncol; 2015 Jul; 8():90. PubMed ID: 26208715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
    Salami K; Alkayed K; Halalsheh H; Hussein AA; Riziq M; Madanat F
    Hematol Oncol Stem Cell Ther; 2013 Mar; 6(1):34-41. PubMed ID: 23664604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Guo Y; Liu TF; Yang WY; Wang SC; Ruan M; Chen XJ; Zhang L; Liu F; Zou Y; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):634-7. PubMed ID: 26108329
    [No Abstract]   [Full Text] [Related]  

  • 38. Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Watanabe A; Chansu S; Ogawa A; Asami K; Imamura M
    Pediatr Int; 2013 Jun; 55(3):e56-8. PubMed ID: 23782380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Philadelphia chromosome-positive acute lymphoblastic leukemia and Down syndrome.
    Tamaura M; Iwasaki F; Yokosuka T; Fukuda K; Hamonoue S; Goto H
    Pediatr Int; 2016 Aug; 58(8):794-7. PubMed ID: 27325175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucormycosis during Imatinib treatment: case report.
    Crisan AM; Ghiaur A; Stancioaca MC; Bardas A; Ghita C; Manea CM; Ionescu B; Coriu D
    J Med Life; 2015; 8(3):365-70. PubMed ID: 26351543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.